Forbes profiles Glenmark's R&D moves

Tools

Forbes profiles Glenmark Pharmaceuticals, the Indian drugmaker that's making the switch from a generics company to an innovative drug developer. CEO Glenn Saldanha has a strategy: develop new drugs through the early stages and license them out to deal-hungry pharma companies looking for later-stage programs. "There's a risk in developing these molecules, and we wanted to pass on this risk," Saldanha tells Forbes. "Plus we've always believed that the real growth is in emerging markets." Report